Literature DB >> 23169485

Immunoparesis and monoclonal gammopathy of undetermined significance are disassociated in advanced age.

Benjamin M Cherry1, Rene Costello, Adriana Zingone, Jason Burris, Neha Korde, Elisabet Manasanch, Mary Kwok, Christina Annunziata, Mark J Roschewski, Eric A Engels, Ola Landgren.   

Abstract

Immunoparesis and a skewed serum free light chain (FLC) ratio are indicators of immune dysfunction predictive of progression from monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM). Previous studies have reported increased prevalence of MGUS by age, but no study has examined the relationship between immunoparesis and abnormal FLC ratios in the elderly. We screened 453 older adults (median age, 80 years; range, 65-96) to characterize the patterns of immunoparesis and abnormal FLC ratio in relation to MGUS. We defined MGUS in 4.4% of the subjects; the prevalence was 12.5% among individuals of >90 years. In MGUS (vs. non-MGUS) cases, immunoparesis and abnormal FLC ratios were detected in 70.0% (vs. 49.0%; P = 0.07) and 50.0% (vs. 12.9%; P = 0.0001), respectively. Based on small numbers, MGUS patients with abnormal FLC ratio were borderline (P = 0.07) more likely to have immunoparesis. Overall, the prevalence of immunoparesis varied in a nonlinear fashion, with lowest frequencies in the youngest and oldest groups. Our observed disassociation between MGUS prevalence and impaired immunoglobulin production suggests that separate mechanisms are involved in the development of MGUS and immunoparesis in advanced age. These findings emphasize the need for molecularly defined methods to characterize myeloma precursor states and better predict progression to MM.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23169485      PMCID: PMC5572208          DOI: 10.1002/ajh.23355

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  25 in total

1.  Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States.

Authors:  Ola Landgren; Gloria Gridley; Ingemar Turesson; Neil E Caporaso; Lynn R Goldin; Dalsu Baris; Thomas R Fears; Robert N Hoover; Martha S Linet
Journal:  Blood       Date:  2005-10-06       Impact factor: 22.113

2.  The influence of age on T cell generation and TCR diversity.

Authors:  Keith Naylor; Guangjin Li; Abbe N Vallejo; Won-Woo Lee; Kerstin Koetz; Ewa Bryl; Jacek Witkowski; James Fulbright; Cornelia M Weyand; Jörg J Goronzy
Journal:  J Immunol       Date:  2005-06-01       Impact factor: 5.422

3.  Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study.

Authors:  Angela Dispenzieri; Jerry A Katzmann; Robert A Kyle; Dirk R Larson; L Joseph Melton; Colin L Colby; Terry M Therneau; Raynell Clark; Shaji K Kumar; Arthur Bradwell; Rafael Fonseca; D F Jelinek; S Vincent Rajkumar
Journal:  Lancet       Date:  2010-05-15       Impact factor: 79.321

Review 4.  Immunoaging induced by hematopoietic stem cell aging.

Authors:  Jianwei Wang; Hartmut Geiger; K Lenhard Rudolph
Journal:  Curr Opin Immunol       Date:  2011-08       Impact factor: 7.486

5.  High prevalence of polyclonal hypergamma-globulinemia in adult males in Ghana, Africa.

Authors:  Francis Buadi; Ann W Hsing; Jerry A Katzmann; Ruth M Pfeiffer; Adam Waxman; Edward D Yeboah; Richard B Biritwum; Yao Tettey; Andrew Adjei; Lisa W Chu; Angelo DeMarzo; George J Netto; Angela Dispenzieri; Robert A Kyle; S Vincent Rajkumar; Ola Landgren
Journal:  Am J Hematol       Date:  2011-06-14       Impact factor: 10.047

6.  Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirus-specific T cells in the very elderly.

Authors:  Sine Reker Hadrup; Jan Strindhall; Tania Køllgaard; Tina Seremet; Boo Johansson; Graham Pawelec; Per thor Straten; Anders Wikby
Journal:  J Immunol       Date:  2006-02-15       Impact factor: 5.422

7.  Racial disparities in incidence and outcome in multiple myeloma: a population-based study.

Authors:  Adam J Waxman; Pamela J Mink; Susan S Devesa; William F Anderson; Brendan M Weiss; Sigurdur Y Kristinsson; Katherine A McGlynn; Ola Landgren
Journal:  Blood       Date:  2010-09-07       Impact factor: 22.113

8.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.

Authors:  Ola Landgren; Robert A Kyle; Ruth M Pfeiffer; Jerry A Katzmann; Neil E Caporaso; Richard B Hayes; Angela Dispenzieri; Shaji Kumar; Raynell J Clark; Dalsu Baris; Robert Hoover; S Vincent Rajkumar
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

9.  New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.

Authors:  Ernesto Pérez-Persona; María-Belén Vidriales; Gema Mateo; Ramón García-Sanz; Maria-Victoria Mateos; Alfonso García de Coca; Josefina Galende; Guillermo Martín-Nuñez; José M Alonso; Natalia de Las Heras; José M Hernández; Alejandro Martín; Consuelo López-Berges; Alberto Orfao; Jesús F San Miguel
Journal:  Blood       Date:  2007-06-18       Impact factor: 22.113

10.  Immunity, ageing and cancer.

Authors:  Evelyna Derhovanessian; Rafael Solana; Anis Larbi; Graham Pawelec
Journal:  Immun Ageing       Date:  2008-09-24       Impact factor: 6.400

View more
  2 in total

Review 1.  Clinical Considerations for Immunoparesis in Multiple Myeloma.

Authors:  Michael Chahin; Zachery Branham; Ashley Fox; Christian Leurinda; Amany R Keruakous
Journal:  Cancers (Basel)       Date:  2022-05-03       Impact factor: 6.575

Review 2.  Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma.

Authors:  Alessandro Allegra; Vanessa Innao; Andrea Gaetano Allegra; Marta Pugliese; Eleonora Di Salvo; Elvira Ventura-Spagnolo; Caterina Musolino; Sebastiano Gangemi
Journal:  Int J Mol Sci       Date:  2019-06-10       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.